Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: The Johnson & Johnson logo is displayed on a screen on the floor of the NYSE in New York (Reuters) - Johnson & Johnson ...

Johnson & Johnson’s top executive should be forced to testify about claims that the company illegally marketed the antipsychotic drug Risperdal, which allegedly caused boys to grow breasts, lawyers ...

WASHINGTON - Johnson & Johnson has tentatively agreed to settle a single misdemeanor criminal charge related to a multiyear government investigation into the marketing of its psychiatric drug ...

Johnson & Johnson promoted illegal marketing of its antipsychotic drug Risperdal by paying physicians to give favorable speeches, subsidizing golf trips and even having sales staff “butter up doctors” ...

Johnson & Johnson, still reeling from settling two Ohio opioid-related lawsuits for more than $20 million, was slapped with an $8 billion judgment on Tuesday over its antipsychotic drug Risperdal. A ...

Now that Johnson & Johnson has agreed to pay $158 million to settle a lawsuit in which the Texas Attorney General charged the drugmaker with a whopper of a scheme to illegally promote its Risperdal ...

In a blow to Johnson & Johnson, the company was ordered last Friday to pay $70 million to a male Tennessee teenager who claimed its Risperdal antipsychotic pill caused him to grow enlarged breasts.

A jury in Philadelphia said Tuesday that Johnson & Johnson must pay $8 billion in punitive damages to a man who previously won $680,000 over his claims that the New Brunswick-based company failed to ...

More than two years after Johnson & Johnson settled a lawsuit with a 21-year-old man who experienced an adverse side effect from Risperdal, hundreds of other young male plaintiffs are pursuing claims ...

A judge on Friday took an axe to a legal award against Johnson & Johnson — chopping the settlement from $8 billion to $6.8 million — in the case of a man who said the company failed to warn consumers ...

The FDA told Johnson & Johnson (JNJ) in 1997 that its request to market the antipsychotic drug Risperdal for children was "without any justification." In the following years, J&J's army of ...